Comparison of the safety and efficacy of the new method of en-bloc and conventional monopolar transurethral resection in the management of primary non-muscle-invasive bladder cancer

Objective: to comparе the safety and efficacy of the new method of en-bloc transurethral resection (TUR) and conventional TUR in management of primary non-muscle-invasive bladder cancer, and investigate long-term effects on tumour recurrence and progression.

Materials and methods. A total of 914 patients with primary non-muscle-invasive bladder cancer were treated using TUR of bladder at the Minsk City Clinical Oncologic Dispensary in 2005 to 2016. For final analysis the data was underwent many-stage random sampling. Randomization was stratified according to sex and age, category T, tumour grade, EORTC risk groups. In total, 273 patients were selected: 136 in the new method of en-bloc TUR group (a study group) and 137 in the conventional TUR group (a control group). The new method of en-bloc TUR is based on using impulses of high-frequency current applied to the active electrode of the resectoscope. The impulse sequence and individual impulse duration within the interval from 0.1 to 1 second are controlled in the course of the operation. Five-year follow-up data of operative management were analyzed.

Results. In event of the new method of en-bloc TUR there were no perioperative complications and no cases of conversion to conventional TUR. Postoperative complications were less frequently observed in the new method group compared with conventional TUR group. There were significant differences with major priority to the new method of en-bloc TUR in median time to recurrence (р = 0.032) and progression (р = 0.001), 5-year survival to recurrence (р = 0.0001) and progression (р = 0.001), 5-year cancer-specific survival (р = 0.033) and overall survival (р = 0.045) of patients.

Conclusion. The new method of en-bloc TUR of non-muscle-invasive bladder cancer was more effective than conventional TUR in reducing rates of intraand postoperative complications, and at the same time was applicable in all clinical cases, regardless of the tumor location in the bladder lumen, its size, vascularization, and growth pattern. The new method of en-bloc TUR also significantly improved the long-term cancer treatment results in patients with primary non-muscle-invasive bladder cancer.

1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin 2018;68(1):7–30. DOI: 10.3322/caac.21442.

2. Heney N., Ahmed S., Flanagan M. et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130(6): 1083–6. DOI: 10.1016/S00225347(17)51695-X.

3. Svatek R.S., Hollenbeck B.K., Holmang A. et al. The economics of bladder cancer: cost and considerations of caring for this disease. Eur Urol 2014;66(2):253–62. DOI: 10.1016/j.eururo.2014.01.006.

4. Maurice M., Vricella G., MacLennan G. et al. Endoscopic snare resection of bladder tumors: evaluation of an alternative technique for bladder tumor resection. J Endourol 2012;26(6):614–7. DOI: 10.1089/end.2011.0587.

5. Fritsche H., Otto W., Eder F. et al. Water-jet-aided transurethral dissection of urothelial carcinoma: a prospective clinical study. J Endourol 2011;25:1599–603. DOI: 10.1016/s1569-9056(11)60529-0.

6. Wolters M., Kramer M., Becker J. et al. Tm: YAG laser en bloc mucosectomy for accura staging of primary bladder cancer: early experience. World J Urol 2011;29:429–32. DOI: 10.1007/s00345011-0686-z.

7. Liu H., Wu J., Xue S. et al. Comparison of the safety and efficacy of conventional monopolar and 2-micron laser transurethral resection in the management of multiple nonmuscle-invasive bladder cancer. J Int Med Res 2013;41(4):984–92. DOI: 10.1177/0300060513477001.

8. Chen X., Liao J., Chen L. et al. En bloc transurethral resection with 2-micron continuouswave laser for primary non-muscleinvasive bladder cancer: a randomized controlled trial. World J Urol 2015;33:989–95. DOI: 10.1007/s00345014-1342-1.

9. Sureka S., Agarwal V., Agnihotri S. et al. Is en-bloc transurethral resection of bladder tumor for non-muscle invasive bladder carcinoma better than conventional technique in terms of recurrence and progression? A prospective study. Indian J Urol 2014;30(2):144–9. DOI: 10.4103/09701591.126887.

10. Kramer M., Altiery V., Hurl R. et al. Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer. Eur Urol Focus 2017;3(6):567–76. DOI: 10.1016/j.euf.2016.12.004.

11. Masanskiy I.L., Krasny S.A. The new en bloc transurethral resection in treatment of non-muscle-invasive bladder cancer: features of surgical technique and assessment of the immediate results. Innovatsionnye tekhnologii v meditsine = Innovative Technology Medicine 2018;6(2):162–71. (In Russ.).

12. Sylvester R.J., van der Meijden A.P., Oosterlinck W. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466. DOI: 10.1016/j.eururo.2005.12.031.

13. Sobin L.H., Gospodarowicz M.K., Wittekind C. TNM classification of malignant tumors. UICC International Union Against Cancer. 7th edn. Wiley-Blackwell, Chichester, 2009.

14. Martin-Doyle W., Leow J.J., Orsola A. et al. Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 2015;33(6):643–50. DOI: 10.1200/JCO.2014.57.6967.

15. Koch M.O., Smith Jr. Natural history and surgical management of superficial bladder cancer (stages Ta/T1/CIS). In: Comprehensive Textbook of Genitourinary Oncology. Chapter 26. Lippincott Williams and Wilkins, Baltimore, 1996. Pp. 405–415.

16. Woldu S.L., Bagrodia A., Lotan Y. Guideline of guidelines: non-muscle-invasive bladder cancer. BJU Int 2017;119(3):371– 80. DOI: 10.1111/bju.13760.

17. Rolevich A., Minich A., Nabebina T. et al. Surgeon has a major impact on long-term recurrence risk in patients with nonmuscle invasive bladder cancer. Cent European J Urol 2016;69(2):170–7. DOI: 10.5173/ ceju.2016.795.

18. Wilby D., Thomas K., Ray E. et al. Bladder cancer: new TUR techniques. World J Urol 2009;27(3):309–12. DOI: 10.1007/s00345-009-0398-9.

19. Herr H.W., Donat S.M. A restaging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006;97:1197–8. DOI: 10.1016/S00225347(18)33065-9.

20. Liem E.I., de Reijke T.M. Can we improve transurethral resection of the bladder tumour for nonmuscle invasive bladder cancer? Curr Opin Urol 2017;27(2):149–55. DOI: 10.1097/MOU.0000000000000370.

21. Cumberbatch M.G.K., Foerster B., Catto J.W.F. et al. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol 2018;73(6):925–33. DOI: 10.1016/j.eururo.2018.02.014.

22. Hendricksen K., Aziz A., Bes P. et al. Discrepancy between European Association of Urology Guidelines and daily practice in the management of non-muscle-invasive bladder cancer: results of European survey. Eur Urol 2016;15(3):216. DOI: 10.1016/j.euf.2017.09.002.

23. Lamm D., Blumenstein B., Crissman J. еt al. Maintenance bacillus CalmetteGuerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized southwest oncology group study. J Urol 2000;163(4):1124–9. DOI:10.1016/s00225347(05)67707-5.

24. Oddens J., Brausi M., Sylvester R. еt al. Final results of an EORTC-GU Cancer Group randomized study of maintenance bacillus Calmette-Guerin immunotherapy in intermediateand highrisk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462–72. DOI: 10.1016/j.eururo.2012.10.039.

25. Xishuang S., Deyong Y., Xiangyu C. et al. Comparing the safety and efficiency of conventional monopolar, plasmakinetic, and holmium laser transurethral resection of primary non-muscle invasive bladder cancer. J Endourol 2010;24(1):69–73. DOI: 10.1089/end.2009.0171.

26. Kitamura K., Kataoka K., Fujioka H. et al. Transurethral resection of a bladder tumor by the use of a polypectomy snare. J Urol 1980;124(6):808–9. DOI: 10.1016/s00225347(17)55675-x.

27. Bach T., Muschter R., Herrman T.R. et al. Technical solutions to improve the management of non-muscle-invasive transitional cell carcinoma: summary of a European Assoсiation of Urology Section for Uro-Technology (ESUT) expert meeting and current and future pers. BJU Int 2015;115:14–23. DOI: 10.1111/bju.12664.

28. Kramer M., Rassweiler J., Klein J. et al. En bloc resection of urothelium carcinoma of the bladder (EBRUC): a European multicenter study to compare safety, efficacy, and outcome of laser and electrical en bloc transurethral resection of bladder tumor. World J Urol 2015;33(12):1937–43. DOI: 10.1007/s00345-015-1568-6.

29. Martov A.G., Ergakov D.V., Baykov N.A. et al. Transurethral en bloc resection of bladder tumors. Onkourologiya = Cancer Urology 2015;11(1):41–9. (In Russ.).

30. Naselli A., Puppo P. En Bloc Transurethral resection of bladder tumors: a new standard? J Endourol 2017;31(S1):20–4. DOI: 10.1089/end.2016.0534.